Imiquimod: mode of action

@article{Schn2007ImiquimodMO,
  title={Imiquimod: mode of action},
  author={M. P. Sch{\"o}n and Mp Sch{\"o}n},
  journal={British Journal of Dermatology},
  year={2007},
  volume={157}
}
Objective  Since imiquimod, a nucleoside analogue of the imidazoquinoline family, has shown efficacy against many tumour entities, its mode of action has become a focus of scientific interest. 
Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
TLDR
The potential use of TLR7 agonists in early stages of COVID-19 is discussed, with implications for the generation of anti-viral immunity and management of coronaviruses. Expand
Imiquimod: The biochemical mechanisms of immunomodulatory and anti-inflammatory activity
TLDR
Detailed analysis of the published data suggests that the biological activity of imiquimod can not be explained only by its interaction with TLR7, and certain evidence exists that imquimod directly interacts with adenosine receptors and other molecules that regulate synthesis of cyclicAdenosine monophosphate. Expand
Pharmacokinetics and toxicity of intravesical TMX‐101: a preclinical study in pigs
• To study the pharmacokinetic and toxicity profile of intravesically administered TMX‐101, with its active ingredient R‐837, a synthetic Toll‐like receptor (TLR)‐7 agonist, in a pig model.
Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity
TLDR
It is concluded that EAPB0203, EAPb0503, as well as imiquimod, interact with tubulin through the colchicine binding site, and that the cytotoxic activity of E APB0 203,EAPB0503 and imiquIMod is correlated to their tubulin inhibiting effect. Expand
Design, Development, and Characterization of Imiquimod-loaded Chitosan Films
University of Minnesota M.S. thesis. March 2017. Major: Pharmaceutics. Advisors: Timothy Wiedmann, Swayam Prabha. 1 computer file (PDF); iv, 43 pages.
Aldara®‐induced skin inflammation: studies of patients with psoriasis
The application of Aldara® cream containing 5% imiquimod stimulates Toll‐like receptor 7/8 on plasmacytoid dendritic cells, thereby producing a potent immunomodulatory effect. This has been reportedExpand
Acute Exacerbation of Myasthenia Gravis with Topical Imiquimod Use
TLDR
A patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna who was halted after 2 weeks when the patient reported itching and irritating sensations in his throat, consistent with previous myASThenia exacerbations. Expand
Efficacy of the Imiqualine analog EAPB0503 against Cutaneous Leishmaniasis : A promising new treatment paradigm
TLDR
The findings show the effect of Imiquimod against both strains especially, the aggressive L. tropica strain, and show that EAPB0503 displays a more potent in vitro leishmanicidal activity than ImiquIMod. Expand
Imiquimod in the treatment of anogenital warts
TLDR
The current knowledge on topical treatment of anogenital warts with imiquimod monotherapy or in combination with other methods is presented, focusing on the treatment of immunocompetent patients, immunosuppressed patients (HIV positive) and pregnant women. Expand
IMIQUIMOD - A TOLL LIKE RECEPTOR 7 AGONIST - IS AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
TLDR
Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity and preclinical and clinical trials are proposed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Efficacy of imiquimod for the expression of Bcl‐2, Ki67, p53 and basal cell carcinoma apoptosis
TLDR
Imiquimod is a modifier of the immune response that has been proven to be an effective treatment for basal cell carcinoma (BCC) and its mechanism of action is still unknown. Expand
Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production.
TLDR
It is determined that the in vivo antiviral activity can be attributed to the ability of these molecules to induce the production of cytokines, especially interferon (IFN), in this model. Expand
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
  • M. Stanley
  • Medicine
  • Clinical and experimental dermatology
  • 2002
TLDR
Imiquimod has been shown to be significantly more effective than placebo in clearing genital warts, and mechanism of action studies indicate that this is related to the ability to generate proinflammatory cytokines and a Th1 response. Expand
Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod
TLDR
Experimental and clinical data indicate that imiquimod also possesses considerable direct pro-apoptotic activity against tumor cells both in vitro and in vivo. Expand
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
TLDR
The antitumor effects of imiquimod were significantly abrogated by an antiserum to murine IFN-alpha, suggesting that the antitumors effect was to a substantial extent mediated by IFN induction. Expand
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
TLDR
Tumor cells became more susceptible to apoptosis through decreased Bcl-2 expression after treatment with 5% imiquimod cream, and induced a massive increase in macrophage peritumoral and intratumoral infiltration. Expand
Imiquimod: a topically applied link between innate and acquired immunity.
TLDR
Tumor cells became more susceptible to apoptosis through decreased Bcl-2 expression after treatment with 5% imiquimod cream and induced a massive increase in macrophage peritumoral and intratumoral infiltration. Expand
Imiquimod and resiquimod as novel immunomodulators.
TLDR
The imidazoquinolinamines imquimod and resiquimod have demonstrated potency as inducers of IFN-alpha and other cytokines both in vitro and in vivo and may find roles in the therapy of cancers and as vaccine adjuvants. Expand
Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro.
The low-molecular-weight immunomodulator drug candidate, imiquimod (R-837), and its hydroxylated metabolite R-842, induce interferon-alpha (IFN-alpha) in human blood cells in vitro when tested inExpand
The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion.
TLDR
It is demonstrated here that imiquimod induces activation of the transcription factor NF-kappaB and the downstream production of proinflammatory cytokines in the absence of TLR7 and TLR8, and appears to suppress an important feedback mechanism of inflammation by antagonism of adenosine receptor-dependent increase of cAMP and a concomitant receptor-independent inhibition of camp production. Expand
...
1
2
3
4
5
...